ArticleKidney international reports2024
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis.
Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm.Nature reviews. Nephrology · 2026Review
- When Blood Proteins Reveal What Transcripts Miss: Immune Cell Priming and the Road to Prognostic Biomarkers in Lupus.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- A Review and Future Perspective on Renal Outcome Definitions in Lupus Nephritis.ACR open rheumatology · 2026Review
- Increased Type I Interferon Activity with Concurrent Plasmablast Expansion Identifies Systemic Lupus Erythematosus Patients with Poor Outcomes.International journal of molecular sciences · 2026Article
- Role of lupus nephritis classification systems in everyday clinical practice: a questionnaire-based survey of the Renal Pathology Society (RPS).Clinical kidney journal · 2026Article
- Article
- High fat diet remodels the gene regulatory networks in the preoptic area.Scientific reports · 2026Article
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- Accelerated immunosenescence in SLE: current evidence and clinical translation.Frontiers in immunology · 2026Review
- MX2 and IRF7 are Associated With Disease Activity and Renal Involvement in Systemic Lupus Erythematosus: An Exploratory Study.Journal of immunology research · 2026Article
- Dysregulation of innate and adaptive lymphoid immunity may have implications for symptom attribution and predict responses to targeted therapies in neuropsychiatric systemic lupus erythematosus.Journal of translational autoimmunity · 2025Article
- Identification of childhood-onset lupus nephritis through integrative bioinformatics: otoferlin as a novel biomarker.Pediatric research · 2025Article
- Benchmarking single-sample gene set scoring methods for application in precision medicine.Briefings in bioinformatics · 2025Article
- Lupus nephritis.Nature reviews. Disease primers · 2025Review
- Comprehensive Profiling of Cytokines and Growth Factors: Pathogenic Roles and Clinical Applications in Autoimmune Diseases.International journal of molecular sciences · 2025Review
- Review
- Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression.Rheumatology (Oxford, England) · 2024Article
- Immune Mechanisms and Biomarkers in Systemic Lupus Erythematosus.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Current therapeutic management of lupus nephritis (LN) fails to induce long-term remission in over 50% of patients, highlighting the urgent need for additional options. Methods: We analyzed differentially expressed genes (DEGs) in peripheral blood from patients with active LN ( Results: Replicated gene modules qualified for correlation analyses with serologic markers, and regulatory network and druggability analysis. Unsupervised coexpression network analysis revealed 20 dysregulated gene modules and stratified the active LN population into 3 distinct subgroups. These subgroups were characterized by low, intermediate, and high interferon (IFN) signatures, with differential dysregulation of the "B cell" and "plasma cells/Ig" modules. Drugs annotated to the IFN network included CC-motif chemokine receptor 1 (CCR1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and irinotecan; whereas the anti-CD38 daratumumab and proteasome inhibitor bortezomib showed potential for counteracting the "plasma cells/Ig" signature. Conclusion: IFN upregulation and B and plasma cell gene dysregulation patterns revealed 3 subgroups of LN, which may not necessarily represent distinct disease phenotypes but rather phases of the inflammatory processes during a renal flare, providing a conceptual framework for precision medicine in LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.